Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)
Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia
1 other identifier
observational
35
1 country
1
Brief Summary
Triggering receptor expressed on myeloid cells (TREM)-1 is a recently described molecule that plays an important role in myeloid cell-activated inflammatory responses. The aim of this study was to investigate the evolutional change of soluble TREM-1 (sTREM-1) in bronchoalveolar lavage (BAL) fluid of clinically diagnosed ventilator-associated pneumonia (VAP) and its correlation with response to treatment and outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2006
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 11, 2009
CompletedFirst Posted
Study publicly available on registry
September 14, 2009
CompletedSeptember 15, 2009
September 1, 2009
1.3 years
September 11, 2009
September 14, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
mortality
18 months
Study Arms (1)
Ventilator-associated pneumonia
Interventions
The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
Eligibility Criteria
Patients who were clinically suspected to have VAP were enrolled in the study. VAP was clinically diagnosed with a new infiltrate on a chest radiograph in a patient receiving mechanical ventilation for more than 48 hr with at least one of the following: purulent tracheal secretions, a body temperature \>38°C or \<36°C, and leukocytosis (WBC \> 10,000/mm³) or leukopenia (WBC \< 4000/mm³)
You may qualify if:
- adult patients (older than 18 years)with clinically suspected VAP
You may not qualify if:
- mechanically ventilated patients post cardiopulmonary resuscitation
- patients with end stage diseases with life expectancy less than 3 months
- patients with solid or hematology transplantation
- patients on immunosuppressive agents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mackay Memorial Hospital
Taipei, 106, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chien Liang Wu, MD
Mackay Memorial Hospital, Taipei, Taiwan
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 11, 2009
First Posted
September 14, 2009
Study Start
August 1, 2006
Primary Completion
December 1, 2007
Study Completion
September 1, 2008
Last Updated
September 15, 2009
Record last verified: 2009-09